Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets
Cristiana Bianco, Elia Casirati, Francesco Malvestiti, et al.
JHEP Reports (2021) Vol. 3, Iss. 3, pp. 100284-100284
Open Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload
Riina Harjumäki, Chris S. Pridgeon, Magnus Ingelman‐Sundberg
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8221-8221
Open Access | Times Cited: 149
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 96
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women
Alessandro Cherubini, Mahnoosh Ostadreza, Oveis Jamialahmadi, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2643-2655
Open Access | Times Cited: 56
Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Metabolism: Insights into Health and Disease
Sébastien Molière, Amélie Jaulin, Catherine Tomasetto, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10649-10649
Open Access | Times Cited: 43
A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers
John B. Whitfield, Tae‐Hwi Schwantes‐An, Rebecca Darlay, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 275-282
Open Access | Times Cited: 59
C–C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease
Zhiwen Fan, Xinyue Sun, Xuelian Chen, et al.
JHEP Reports (2023) Vol. 5, Iss. 9, pp. 100805-100805
Open Access | Times Cited: 24
Genetics of MASLD: The State of Art Update.
Silvia Sookoian, Yaron Rotman, Luca Valenti
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 11, pp. 2177-2187.e3
Closed Access | Times Cited: 15
Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease
Oveis Jamialahmadi, Antonio De Vincentis, Federica Tavaglione, et al.
Nature Medicine (2024)
Open Access | Times Cited: 15
Exploring the role of genetic variations in NAFLD: implications for disease pathogenesis and precision medicine approaches
Seyedeh Kosar Mahmoudi, Shadi Tarzemani, Taha Aghajanzadeh, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 14
PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Alessandro Cherubini, Elia Casirati, Melissa Tomasi, et al.
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 12, pp. 1033-1043
Open Access | Times Cited: 54
Hepatoprotective effects of Xiaoyao San formula on hepatic steatosis and inflammation via regulating the sex hormones metabolism
Xiaoli Mei, Wu Shuyi, Si-Lan Wu, et al.
World Journal of Hepatology (2024) Vol. 16, Iss. 7, pp. 1051-1066
Open Access | Times Cited: 7
Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Tanmoy Banerjee, Arnab Sarkar, Sk Zeeshan Ali, et al.
Planta Medica (2024) Vol. 90, Iss. 09, pp. 675-707
Open Access | Times Cited: 6
Anti-Angiogenic Effects of Natural Compounds in Diet-Associated Hepatic Inflammation
Sara Novi, Vincenzo Vestuto, Pietro Campiglia, et al.
Nutrients (2023) Vol. 15, Iss. 12, pp. 2748-2748
Open Access | Times Cited: 13
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction
Luca Valenti, Armando Tripodi, Vincenzo La Mura, et al.
JHEP Reports (2022) Vol. 4, Iss. 12, pp. 100598-100598
Open Access | Times Cited: 20
Antiangiogenic Effects of Natural Compounds in Hepatic Inflammation
Sara Novi, Vincenzo Vestuto, Pietro Campiglia, et al.
(2023)
Open Access | Times Cited: 11
Intestinal microbiota promoted NiONPs-induced liver fibrosis via effecting serum metabolism
Jiarong Tang, Hongjun Zhao, Kun Li, et al.
Ecotoxicology and Environmental Safety (2024) Vol. 270, pp. 115943-115943
Open Access | Times Cited: 4
Integrative Analysis of PPAR and Immune Pathways in Hepatocellular Carcinoma: Constructing a Prognostic Risk Model Using TCGA Data
Jiao Li, Yang Chen, Lei Cao
Journal of Clinical Pharmacy and Therapeutics (2025) Vol. 2025, Iss. 1
Open Access
Advanced 3D bioprinted liver models with human-induced hepatocytes for personalized toxicity screening
Yue Ma, Runbang He, Bo Deng, et al.
Journal of Tissue Engineering (2025) Vol. 16
Open Access
Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives
Yoonji Ha, In-Ju Jeong, Tae Hyun Kim
Biomedicines (2022) Vol. 10, Iss. 10, pp. 2530-2530
Open Access | Times Cited: 18
The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease
Lorenz Balcar, Bernhard Scheiner, Markus Urheu, et al.
Digestive and Liver Disease (2023) Vol. 55, Iss. 8, pp. 1072-1080
Open Access | Times Cited: 10
Polygenic risk score in cirrhosis: Does the etiology matter?
Marta Alonso‐Peña, M. Arias, Joaquin Cabezas, et al.
Hepatology Communications (2025) Vol. 9, Iss. 2
Closed Access
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals
Serena Pelusi, Cristiana Bianco, Massimo Colombo, et al.
Liver International (2023) Vol. 43, Iss. 7, pp. 1593-1603
Open Access | Times Cited: 9
Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases
Joseph L. Dempsey, George N. Ioannou, Rotonya M. Carr
Seminars in Liver Disease (2023) Vol. 43, Iss. 04, pp. 367-382
Closed Access | Times Cited: 9
Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Concepción Gómez, Luma Melo, David Martí‐Aguado, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. 1, pp. 1-15
Open Access | Times Cited: 14
Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
Eleftheria Galatou, Elena A. Mourelatou, Sophia Hatziantoniou, et al.
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1060-1060
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top